Press Room

CMTA announced today a $423,000 investment to address diagnostic gaps and drive new CMT gene discoveries. Led by CMTA-STAR Advisory Board Member Stephan Züchner, MD, PhD, at The GENESIS Project Foundation, this investment will expand ...

Welcome to Episode 2 of the Simply CMT Podcast! Join us as we talk with Jonah Berger, CMTA National Youth Programs Manager and Director of Camp Footprint. Jonah shares his journey living with CMTX, the ...

Alesta Therapeutics, a CMTA-STAR Alliance Partner focused on developing therapies for rare diseases, recently announced a successful financing that will allow them to address CMT through its innovative therapeutic candidate, ALE2. According to the company, ...

Charcot-Marie-Tooth disease (CMT) is the most common inheritable peripheral neuropathy, affecting millions of people worldwide. Despite its prevalence, many people are unfamiliar with CMT and its impact. That’s why CMTA created a new video to explain ...

What is the Nervosave Survey? CMTA-STAR Alliance Partner Nervosave Therapeutics, a France-based biotech company, is seeking participants for an online survey to understand patient perspectives on a new genetic therapy under development for CMT1A. According to ...